Journals / Retina-Vitreus / 2022 / Cilt: 31 - Sayı: 1

Faricimab- Can it Reset the Recent Safety Doomed Innovations in Retinal Pharmacotherapy?

Pages
1–3
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We hope that entry of Faricimab might reset the recent safety doomed innovations in retinal pharmacotherapy?

📌 3 Key Takeaways

🎯
Objective & Hypothesis:After the consecutive success of multiple anti-VEGF molecules in the last decade such as ranibizumab, bevacizumab and aflibercept, innovations in the retinal pharmacotherapy has gone through a rough phase in the recent past.
📊
Key Findings & Data:Faricimab is another innovative molecule that has shown excellent safety and efficacy in the phase 3 trials.
💡
Conclusion & Impact:We hope that entry of Faricimab might reset the recent safety doomed innovations in retinal pharmacotherapy?
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

After the consecutive success of multiple anti-VEGF molecules in the last decade such as ranibizumab, bevacizumab and aflibercept, innovations in the retinal pharmacotherapy has gone through a rough phase in the recent past. Multiple promising molecules such as brolucizumab and aflibercept faced drug induced inflammation. Furthermore ranibizumab port delivery system was associated with procedure related vitreous hemorrhage, which though improved after modification in the surgical procedure, still is a challenge. Faricimab is another innovative molecule that has shown excellent safety and efficacy in the phase 3 trials. We hope that entry of Faricimab might reset the recent safety doomed innovations in retinal pharmacotherapy?

🔖

Cite This Article

Sharma, A. (2022). Faricimab- Can it Reset the Recent Safety Doomed Innovations in Retinal Pharmacotherapy?. Retina-Vitreus, Cilt: 31 - Sayı: 1, 1–3. https://ajindex.com/articles/589012

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. . Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015
  2. doi: 10.1136/bjophthalmol-2014-305327. 2. Kunimoto D, Yoon YH, Wykoff CC, et al. CEDAR and SEQUOIA Study Groups. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020
  3. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020
  4. h t t p s: / / w w w. r o c h e. c o m / i n v e s t o r s / u p d a t e s / i n v - update-2020-05-27.htm 5. https://www.roche.com/media/releases/med-cor-2021-02-12. htm 6. Sharma A, Kumar N, Kuppermann BD, et al. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye (Lond). 2019
  5. Sharma A, Kumar N, Kuppermann BD, et al. Ophthalmic biosimilars and biologics-role of endotoxins. Eye (Lond). 2020
  6. doi: 10.1038/s41433-019-0636-3. 8. Sharma A, Kumar N, Kuppermann BD, et al. Brolucizumab: is extended VEGF suppression on the horizon? Eye (Lond). 2020
  7. Sharma A, Kumar N, Parachuri N, et al. Brolucizumab and immunogenicity. Eye (Lond). 2020
  8. Monés J, Srivastava SK, Jaffe GJ, et al. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology. 2020 Nov 15:S0161-6420(20)31075-7. 11. Sharma A, Kumar N, Parachuri N, et al. Brolucizumab- foreseeable workflow in the current scenario. Eye (Lond). 2021 Feb 2. 12. Sharma A, Kumar N, Parachuri N,et al. Correction: Brolucizumab-early real-world experience: BREW study. Eye (Lond). 2021
  9. https://www.nature.com/articles/d41573-020-00127-8. 14. Sharma A, Kumar N, Kuppermann BD, et al. Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye (Lond). 2020
  10. Kunimoto D, Yoon YH, Wykoff CC, et al. CEDAR and SEQUOIA Study Groups. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020
  11. https://www.healio.com/news/ophthalmology/20190402/maple- trial-shows-less-intraocular-inflammation-after-abicipar-use 17. Kiss S, Du